Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Tarsus Pharmaceuticals, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| | 8-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues | 100.0% | 100.0% | | | 100.0% |
| Cost of goods sold | 342.9% | 0.0% | | | 149.8% |
| Gross profit | -242.9% | 100.0% | | | -49.8% |
| Research and development | | 73.1% | | | |
| General and administrative | 174.1% | 44.5% | | | 49.8% |
| EBITDA | -245.9% | -20.8% | | | -199.6% |
| Depreciation | | 0.5% | | | 0.1% |
| EBIT | -245.9% | -21.3% | | | -199.7% |
| Pre-tax income | -240.5% | -24.1% | | | 0.0% |
| Income taxes | 0.0% | 0.1% | | | -0.1% |
| Net income | -240.5% | -24.2% | | | 0.0% |
|